At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VIR Vir Biotechnology, Inc.
Post-Market Trading 01-08 19:33:30 EST
12.48
+4.59
+58.17%
盘后12.56
+0.08+0.64%
19:31 EST
High14.45Low11.47Vol39.48M
Open12.55D1 Closing7.89Amplitude37.77%
Mkt Cap1.72BTradable Cap1.16BTotal Shares137.72M
T/O502.00MT/O Rate42.58%Tradable Shares92.74M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
BRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC
Reuters  ·  01-08 20:57
BRIEF-Vir Biotechnology Announces Encouraging Safety And Efficacy Data In Ongoing Dose Escalation Trials For Dual Masked T-Cell Engagers VIR-5818 In Solid Tumors And VIR-5500 In mCRPC
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Dow Jones  ·  00:58
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Vir Biotechnology Up Over 65%, on Pace for Largest Percent Increase Since January 2021 -- Data Talk
Dow Jones  ·  01-08 23:49
Vir Biotechnology Up Over 65%, on Pace for Largest Percent Increase Since January 2021 -- Data Talk
Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Dow Jones  ·  01-08 23:14
Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Vir Biotechnology Shares up 55.8% on Positive Data From Early-Stage Trials for Tumor Treatments
THOMSON REUTERS  ·  01-08 22:32
Vir Biotechnology Shares up 55.8% on Positive Data From Early-Stage Trials for Tumor Treatments
BUZZ-U.S. STOCKS ON THE MOVE-Twilio, L3Harris, Chart Industries
Reuters  ·  01-08 22:08
BUZZ-U.S. STOCKS ON THE MOVE-Twilio, L3Harris, Chart Industries
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
Blockhead  ·  01-08 22:06
Vir Biotechnology Catapults 62% On Promising Results In Cancer Treatment
BUZZ-Vir jumps on positive data from early-stage trials for tumor treatments
Reuters  ·  01-08 21:17
BUZZ-Vir jumps on positive data from early-stage trials for tumor treatments
Vir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials
TIPRANKS  ·  01-08 20:56
Vir Biotechnology presents safety, efficacy data in VIR-5818 and VIR-5500 trials
Vir Biotechnology Shares up 31.7% Premarket After Early-Stage Trial Data for Prostate Cancer Treatment
THOMSON REUTERS  ·  01-08 20:52
Vir Biotechnology Shares up 31.7% Premarket After Early-Stage Trial Data for Prostate Cancer Treatment
Vir Biotechnology Inc - No Dose-Limiting Crs Observed for Vir-5818 or Vir-5500
THOMSON REUTERS  ·  01-08 20:45
Vir Biotechnology Inc - No Dose-Limiting Crs Observed for Vir-5818 or Vir-5500
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Business Wire  ·  01-08 20:45
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Vir Biotechnology price target lowered to $14 from $15 at BofA
TipRanks  ·  01-08 20:25
Vir Biotechnology price target lowered to $14 from $15 at BofA
BofA Securities Trims Price Target on Vir Biotechnology to $14 From $15, Maintains Neutral Rating
MT Newswires Live  ·  01-08 00:17
BofA Securities Trims Price Target on Vir Biotechnology to $14 From $15, Maintains Neutral Rating
US FDA revokes authorization for four COVID antibody drugs
Reuters  ·  2024-12-24
US FDA revokes authorization for four COVID antibody drugs
US FDA revokes authorization for five COVID treatments
Reuters  ·  2024-12-24
US FDA revokes authorization for five COVID treatments
BRIEF-US FDA Revoked Emergency Use Authorization For Certain COVID Drugs As Of Dec 13
Reuters  ·  2024-12-24
BRIEF-US FDA Revoked Emergency Use Authorization For Certain COVID Drugs As Of Dec 13
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Business Wire  ·  2024-12-18
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Biotechnology's Tobevibart, Elebsiran Receive US, EU Designations for Hepatitis Delta Treatment
MT Newswires Live  ·  2024-12-13
Vir Biotechnology's Tobevibart, Elebsiran Receive US, EU Designations for Hepatitis Delta Treatment
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and Ema Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
THOMSON REUTERS  ·  2024-12-13
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and Ema Prime Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Introduction

Company Name.
Vir Biotechnology, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Issue price:
--